Aims
To determine the frequencies of the genotypes of CYP3A5 and MDR1 and to examine the influence of the polymorphisms of these genes on tacrolimus pharmacokinetics in the Korean population.
Methods
Twenty-nine healthy Koreans who participated in the previous tacrolimus pharmacokinetic study were genotyped for CYP3A4*1B, CYP3A5*3, MDR1 c.1236C→T, MDR1 c.2677G→A/T and MDR1 c.3435C→T. The relationship between the genotypes so obtained and tacrolimus pharmacokinetics observed in the previous study was examined.
Results
No subject in this study had the CYP3A4*1B variant. The observed frequencies of CYP3A5*1/*1, *1/*3, and *3/*3 were 0.069 [confidence interval (CI) -0.023, 0.161], 0.483 (CI 0.301, 0.665) and 0.448 (CI 0.267, 0.629), respectively. AUC0-• for the CYP3A5*1/*1 or *1/*3 genotype was 131.5 Ϯ 44.8 ng h ml -1 (CI 109.6, 153.5), which was much lower compared with the CYP3A5*3/*3 genotype of 323.8 Ϯ 129.3 ng h ml -1 (CI 253.5, 394.1) (P = 2.063E-07). Similarly, Cmax for the CYP3A5*1/*1 or *1/*3 genotype was 11.8 Ϯ 3.4 ng ml -1 (CI 10.1, 13.5), which was also much lower compared with the CYP3A5*3/*3 genotype of 24.4 Ϯ 12.3 ng ml -1 (CI 17.8, 31.1) (P = 0.0001). However, there was no significant difference in tacrolimus pharmacokinetics among the MDR1 diplotypes of CGC-CGC, CGC-TTT, CGC-TGC, TTT-TGC or TTT-TTT (P = 0.2486).
Conclusions
This study shows that the CYP3A5*3 genetic polymorphisms may be associated with the individual difference in tacrolimus pharmacokinetics. An individualized dosage regimen design incorporating such genetic information would help increase clinical efficacy of the drug while reducing adverse drug reactions.
Introduction
Tacrolimus, one of the calcineurin inhibitors, is highly effective in preventing acute rejection after transplantation of solid organs, including the liver and kidney [1] . However, tacrolimus shows high between-and withinsubject variability in pharmacokinetics, with a narrow therapeutic index, necessitating therapeutic drug monitoring to optimize treatment [2] [3] [4] .
It has become clear that the variability in the pharmacokinetics of tacrolimus is largely determined by differences in oral bioavailability [5] . Tacrolimus is a substrate of P-glycoprotein, the product of the multidrug resistance (MDR1) gene and has been known to undergo extensive hepatic metabolism by cytochrome P450 3A4 (CYP3A4) and CYP3A5 [6] [7] [8] . The variability in oral bioavailability of tacrolimus thus has been attributed to individual differences in expression of CYP3A4, CYP3A5 and P-glycoprotein [9] .
A limited number of studies have reported on the association between CYP3A4 variants and the pharmacokinetics of tacrolimus. Hesselink et al. found that CYP3A4*1B carriers require larger dose of tacrolimus to reach target trough concentrations compared with CYP3A4*1 homozygotes [5] . In their work, it was established that the dose requirement for tacrolimus could be affected by CYP3A5 variants. Several studies have reported that the dose-adjusted trough concentration of tacrolimus is much higher in CYP3A5*3/*3 subjects than in *1/*1 or *1/*3 subjects [10] [11] [12] [13] [14] [15] . The CYP3A5*3 variant creates an alternative splice in pre-mRNA and produces aberrant mRNA that does not translate into functional CYP3A5 protein [16] . In contrast, numerous studies have investigated whether the genetic polymorphisms in MDR1, including c.1236C→T, c.2677G→ A/T and c.3435C→T, could affect the pharmacokinetics of tacrolimus, yielding controversial results [9] .
In a previous pharmacokinetic study, we compared the pharmacokinetics of twice-daily dosing of 1-mg tacrolimus capsules of two different formulations in healthy Korean volunteers: Prograf (Astellas Pharma Korea, Inc.), the reference, or conventional formulation, and TacroBell ® (Chong Kun Dang Pharmaceutical Corp., Korea), the test, or newly developed formulation. While no significant difference in formulation was observed, we found high interindividual variability [51-76%, coefficient of variation (CV)] in the pharmacokinetics of tacrolimus and suspected a possible genetic polymorphism as a source of pharmacokinetic variation [17] . In this regard, this study was intended to see if such a possibility existed in the Korean population. Subjects who had participated in the previous tacrolimus pharmacokinetic study were therefore first examined for the frequencies of CYP3A4*1B, CYP3A5*3 and three single nucleotide polymorphisms (SNPs) of MDR1, c.1236C→T, c.2677G→A/T and c.3435C→ T, and then for an association between the resulting genotypes and tacrolimus pharmacokinetics obtained in the previous study.
Materials and methods Subjects
This study was approved by the institutional review board of Yonsei University Medical Centre, Seoul, Korea. A total of 29 unrelated healthy Korean volunteers participated in this study after giving written informed consent. They were recruited from the volunteers who had participated in the previous pharmacokinetic study of two oral formulations of tacrolimus [17] .
Genetic analysis
We investigated the genotype frequencies of CYP3A4*1B (GenBank accession number AC069294), CYP3A5*3 (GenBank accession number AC005020) and three SNPs of MDR1, c.1236C→T, c.2677G→A/T and c.3435C→T (GenBank accession numbers NC000007, NM000927) for the subjects by direct sequencing using an automated genetic analyser (Model 3700; Applied Biosystems, Foster City, CA, USA). The nomenclature of CYP3A4 and CYP3A5 was based on the website http://www.cypalleles.ki.se/. For each subject, one blood sample was collected and DNA was extracted using a purification kit (Qiagen, Hilden, Germany). Haplotype assembly was performed using the Haploview 3.2 program (Broad Institute of Harvard and MIT, Cambridge, MA, USA), based on a standard expectationmaximization algorithm to reconstruct individual haplotypes from population genotype data [18] .
Pharmacokinetic data
For pharmacokinetic data, we used data obtained from the previous pharmacokinetic study, which can be summarized as follows [17] . It was as an open-label, randomized, two-period, cross-over study with a 3-week wash-out period in 29 healthy Korean volunteers. Each subject received two 1-mg capsules of a conventional (reference) or a newly developed (test) oral tacrolimus formulation twice a day, morning and evening (total daily dose of 4 mg). Blood samples were collected before dosing and at 0.5, 1, 1.5, 2, 3, 4, 7, 12, 12.5, 13, 13.5, 14, 15, 16, 19, 24, 36, 48, 72 and 96 h after dosing. Whole blood concentrations were analysed by LC/MS/ MS. Pharmacokinetic parameters such as area under the concentration curve from time zero to infinity (AUC 0-• ), maximum concentration (C max ), time to C max (t max ) and half-life (t 1/2 ) for tacrolimus were estimated by noncompartmental analysis using WinNonlin Professional 4.1. In results, the two formulations were not significantly different and showed similarly large interindividual variation in tacrolimus pharmacokinetics [59.3-61.1% (test) and 50.7-75.6% (reference) in CV]. Therefore, in this study, without loss of generality, only the conventional formulation's pharmacokinetic data were used in examining genetic influences on tacrolimus pharmacokinetics.
Statistical analysis
Differences in pharmacokinetic parameters between the genotype groups were tested using the Wilcoxon rank sum test or the Kruskal-Wallis test. The frequency of CYP3A5*3/*3 genotype was compared with that of the other ethnic groups, using c 2 test. P-values < 0.05 were considered to be statistically significant. Table 1 shows frequency distributions of CYP3A5 and MDR1 genotypes in 29 Korean subjects examined in this study. Each genotype did not deviate from HardyWeinberg equilibrium. Among the CYP3A4*1B, CYP3A5*3 and MDR1 genotypes examined in our study, the CYP3A4*1B genotype was not observed in any subject and the CYP3A5*1/*1 genotype was observed in only two subjects, yielding a frequency of 0.069 [confidence interval (CI) -0.023, 0.161), with CI indicating a 95% CI. In contrast, for the CYP3A5*3 variant, the heterozygous allele was observed in 14 subjects with a frequency of 0.483 (CI 0.301, 0.665), while the homozygous allele was observed in 13 subjects with a frequency of 0.448 (CI 0.267, 0.629). The frequency of CYP3A5*3/*3 observed with our subjects was similar to that of 0.400 (CI 0.268, 0.532) with Chinese (P = 0.5313) or 0.583 (CI 0.512, 0.654) with Japanese (P = 0.1737) [19, 20] . However, some significant differences were also found in the frequency of this genotype. That is, the frequency of CYP3A5*3/*3 genotype was higher in Koreans compared with the frequency of 0.029 (CI -0.027, 0.085) in African-Americans (P = 0.0001), but was much lower compared with the frequency of 0.830 (CI 0.756, 0.904) in Whites (P = 0.0001) [21, 22] . These results suggest that the frequency of CYP3A5*3/*3 genotype is dependent on ethnicity.
Results

Polymorphisms of CYP3A5 and MDR1 in Koreans
The MDR1 haplotypes were estimated from the three MDR1 genotypes at c.1236C→T, c.2677G→A/T and c.3435C→T using a standard expectation-maximization algorithm ( Table 2 ). Three major haplotypes that were relatively commonly observed were TTT, CGC and TGC, accounting for 41.4%, 20.7% and 20.7% of the total haplotype diversity, respectively. The combinations of these three predominant haplotypes constituted the five diplotypes examined in this study, CGC-CGC (3.4%, n = 1), CGC-TTT (17.2%, n = 5), CGC-TGC (10.3%, n = 3), TTT-TGC (31.0%, n = 9) and TTT-TTT (10.3%, n = 3) ( Table 3) .
Pharmacokinetic parameters of tacrolimus
In this study, pharmacokinetic values were given as mean Ϯ SD with 95% CI. Table 4 shows that AUC 0-• for the subject with the CYP3A5*1/*1 or *1/*3 genotype 
Table 4
Tacrolimus pharmacokinetic parameters vs. CYP3A5 genotypes in healthy Koreans (n = 29) values of t max and t 1/2 were similar between the two genotype groups (P = 0.1160, 0.1103, respectively). The genotype differences in AUC 0-• and C max of tacrolimus are visually depicted in Figure 1 .
There was no significant difference in pharmacokinetics of tacrolimus among the five MDR1 diplotype groups (P = 0.2486) ( Table 3) .
Discussion
In the present study, we observed a significant association between the blood concentration of tacrolimus and the CYP3A5*3 variant. Our results show that subjects with the CYP3A5*1/*1 or *1/*3 genotype yield much lower AUC 0-• and C max values than the CYP3A5*3/*3 genotype. To investigate other possibilities that may contribute to such pharmacokinetic differences, demographic factors including age, sex, height and body weight were compared between the two genotype groups. No demographic factor showed a significant difference between the two groups other than age, which showed distributions (mean Ϯ SD) of 31.4 Ϯ 8.3 years for the CYP3A5*1/*1 or *1/*3 genotype vs. 25.6 Ϯ 2.1 years for the CYP3A5*3/*3 genotype (P = 0.0153) ( Table 5) . However, it has been reported that CYP3A activity is not significantly influenced by age [23] .
Several studies have reported the interethnic variation in the pharmacokinetics of tacrolimus [24, 25] . In relation to interethnic differences in the frequency of the CYP3A5*3 allele, Thompson et al. found that the frequency is lowest in sub-Saharan Africa and highest in European and East Asian populations, showing an increasing trend with distance from the equator [26] . Similarly in this work, we found that the CYP3A5*3/*3 genotype was more common in Koreans and Whites than in African-Americans. The interethnic difference in the frequency of CYP3A5*3/*3 genotype may contribute to the interethnic variation in the pharmacokinetics of tacrolimus.
In our subjects, no one had the CYP3A4*1B variant. According to the work by Lamba et al., this genotype was not found in Japanese-Americans or in Chinese- Americans, while frequencies of 2.0-9.6% and 35-67% were observed in Whites and African-Americans, respectively [16] . These findings indicate that the frequency of the CYP3A4*1B allele may vary among ethnic groups.
In our results, no significant difference was found in tacrolimus pharmacokinetics against MDR1 polymorphisms in c.1236C→T, c.2677G→A/T or c.3435C→T, indicating a nonsignificant association between the blood concentration of tacrolimus and these three genotype groups (data not shown). Although many researchers have tried to examine whether these three SNPs could affect the expression and function of MDR1, the results are still controversial [27] . Recently, it has been confirmed that MDR1 c.3435C→T is in significant linkage disequilibrium with c.1236C→T and c.2677G→A/T and the analysis of MDR1 haplotypes may be superior to that of SNPs in revealing genotype-phenotype associations in pharmacokinetic studies [8, [27] [28] [29] .
In our work, we estimated the MDR1 haplotypes from the three MDR1 genotypes at c.1236C→T, c.2677G→A/T and c.3435C→T using a standard expectation-maximization algorithm. Three predominant haplotypes were observed and the combinations of these three haplotypes constituted the five diplotypes, with no significant difference observed in tacrolimus pharmacokinetics among these five MDR1 diplotypes. Thus, although it was found that the subject with CGC-CGC diplotype showed much higher AUC 0-• and C max compared with the other subjects (Table 3) , this may be mainly due to the influence of the CYP3A5*3/*3 genotype of this subject (Table 4) .
In conclusion, our study demonstrates that the CYP3A5 genetic polymorphisms may be associated with the pharmacokinetic variation of tacrolimus in Korean populations. Therefore, dosage regimen design incorporating genetic polymorphisms in CYP3A5 may be of help in identifying the optimal dose for the individual patient. 
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